Oncotype DX (ODX), 21-gene breast cancer (BC) assay, predicts risk of recurrence and benefits of addition of chemotherapy to hormonal therapy for early-stage BC. We previously published a nomogram/calculator that could predict ODX results without performing the test by using clinicopathologic ...
Eight statistical models were computed: Magee equations (ME), Memorial Sloan Kettering simplified risk score (MSK-SRS), Breast Cancer Recurrence Score Estimator (BCRSE), OncotypeDXCalculator (ODXC), new Adjuvant! Online (nAOL), Mymammaprint.com (MyMP), PREDICT, and SiNK. Concordance, negative ...
Circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers combined with clinicopathological risk has potential to better predict recurrence in stage III breast cancer treated with neoadjuvant chemotherapy: a pilot study Kai-Ye Du Shang Wu Yunjiang Liu Breast Cancer Res...
Investigators used a residual cancer burden calculator hosted by MD Anderson that assigns classifications ofpathologic complete response, RCB-1 (minimal burden), RCB-II (moderate burden) or RCB-III (extensive burden). Results showed tight...
"This pooled analysis confirms and expands upon prior findings that RCB index can predict risk of breast cancer recurrence," said Symmans. "This assessment of prognostic risk can be used to accurately determine disease progression and inform treatment choice for breast cancer patients inclusive of ...
Impact of older age and comorbidity on locoregional and distant breast cancer recurrence: A large population-based study Oncol, 25 (1) (2020), pp. e24-e30, 10.1634/theoncologist.2019-0412 View in ScopusGoogle Scholar [7] H. Wildiers, M. Mauer, A. Pallis, A. Hurria, S.G. Mohile, ...
Recurrence. Since I’ve been diagnosed, I’ve lost 6 friends to cancer. I’ve written about this previously: The National Health Service in the UK has a model of calculating breast cancer survivorship based on a patient’s pathology. It is called Predict and the current version is 2.0. Sl...
Locoregional recurrence was defined as disease recurrence in the chest wall and/or regional lymph nodes. Disease-free and overall survival were defined from the date of diagnosis. The residual cancer burden index was calculated using an online calculator.31,32 Patients underwent standardized evaluations...
As a cell proliferation biomarker, Ki-67 is principally used in ER+/HER2− breast cancer. However, the importance and the best cutoff point of Ki-67 in triple-negative breast cancer (TNBC) remains unclear and was evaluated in this study.A total of 1800
Continued observation of the natural history of low-grade ductal carcinoma in situ reaffirms proclivity for local recurrence even after more than 30 years of follow-up. Mod Pathol. 2015;28(5):662–9. https://doi.org/10.1038/modpathol.2014.141. Article PubMed Google Scholar Yonekura R, ...